BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update

BioLineRx Ltd. (NASDAQ:BLRX) saw a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 137,700 shares, a decrease of 23.2% from the September 15th total of 179,200 shares. Based on an average daily volume of 304,700 shares, the days-to-cover ratio is presently 0.5 days.

BioLineRx Stock Performance

BLRX stock traded down $0.03 during midday trading on Tuesday, reaching $0.44. 291,817 shares of the company were exchanged, compared to its average volume of 343,268. BioLineRx has a one year low of $0.43 and a one year high of $1.93. The firm has a market capitalization of $34.79 million, a price-to-earnings ratio of -0.61 and a beta of 1.46. The business has a 50-day moving average price of $0.63 and a two-hundred day moving average price of $0.67. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49.

BioLineRx (NASDAQ:BLRX) last announced its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $3.93 million. Equities research analysts forecast that BioLineRx will post -0.25 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on BioLineRx in a research report on Tuesday. They set a “hold” rating on the stock.

Institutional Trading of BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. PVG Asset Management Corp bought a new stake in BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 61,840 shares of the biotechnology company’s stock, valued at approximately $97,000. BioLineRx accounts for 0.5% of PVG Asset Management Corp’s portfolio, making the stock its 29th biggest position. PVG Asset Management Corp owned 0.09% of BioLineRx as of its most recent SEC filing. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.